吗啡对P2Y12受体拮抗剂药代及药效动力学的影响

发布时间：2018-06-29 23:43

本文选题：吗啡 + PY受体拮抗剂　；参考：《中国药理学通报》2017年08期

【摘要】：吗啡联合P2Y12受体拮抗剂常用于急性心肌梗死患者的治疗。P2Y12受体拮抗剂能快速、强效抑制血小板活性,并降低再发栓塞风险,吗啡为心绞痛治疗的常规用药。既往有研究指出,吗啡能降低急性冠脉综合征患者氯吡格雷的血药浓度、减弱其抗血小板作用,并可能导致较差的预后。基于健康受试者和急性心肌梗死患者的随机试验也证实,吗啡与新型P2Y12受体拮抗剂替格瑞洛与普拉格雷同样存在类似的药物相互作用。尽管心肌梗死患者的治疗中仍存在吗啡合用P2Y12受体拮抗剂,然而,目前综述两药物相互作用的报道较少。因此,该文基于既往实验性、观察性和随机临床研究,概述吗啡与P2Y12受体拮抗剂之间的药物相互作用。
[Abstract]:Morphine combined with P2Y12 receptor antagonists is often used in the treatment of acute myocardial infarction with.P2Y12 receptor antagonists, which can quickly, strongly inhibit platelet activity, and reduce the risk of recurrent thromboembolism. Morphine is a routine medication for the treatment of angina pectoris. Its antiplatelet effect may lead to poor prognosis. A randomized trial based on healthy subjects and patients with acute myocardial infarction has also confirmed that morphine and a new P2Y12 receptor antagonist have similar drug interactions with prasugrel. Although there are still morphine combined P2Y12 receptor antagonists in patients with myocardial infarction However, however, there are few reports on the interaction of two drugs. Therefore, this article is based on previous experimental, observational and randomized clinical studies, summarizing the drug interactions between morphine and P2Y12 receptor antagonists.
【作者单位】：中南大学湘雅医院临床药理研究所;中南大学临床药理研究所遗传药理学湖南省重点实验室;中南大学湘雅医学院附属海口医院药学部;
【基金】：国家科技部“重大新药创制”科技重大专项资助项目(No2013ZX09509107) 国家自然科学基金资助项目(No81373489,81422052,81403018) 湖南省杰出青年基金资助项目(No 13JJ1010)
【分类号】：R969

【相似文献】